Literature DB >> 10930669

Immunity to diphtheria and tetanus in England and Wales.

P A Maple1, C S Jones, E C Wall, A Vyseb, W J Edmunds, N J Andrews, E Miller.   

Abstract

The immunity profile of the English and Welsh population to diphtheria and tetanus has been determined by measuring diphtheria and tetanus antitoxin levels for 3088 and 3142 sera, respectively. Time-resolved fluorimetric immunoassay - DELFIA was used to measure diphtheria antitoxin levels and an in-house, indirect ELISA to measure tetanus antitoxin levels. More than 80% of those aged between 2 and 20-24 years had protective diphtheria antitoxin levels of 0.01 IU/ml, or greater, and more than 80% of those aged between 4 and 35-39 years had protective tetanus antitoxin levels of 0.1 IU/ml, or greater. Only 29% and 53% of those aged 60 and over were protected against diphtheria and tetanus. Two increases of diphtheria antitoxin levels greater than 0.1 IU/ml and tetanus antitoxin levels greater than 1.0 IU/ml were apparent, starting at 4 and 14 years of age, which correspond with the policy of giving a diphtheria and tetanus toxoid booster on school entry and a tetanus plus low-dose diphtheria toxoid (recently introduced) booster to school leavers. This is the first comprehensive study of diphtheria and tetanus immunity in the English and Welsh population and shows that the accelerated schedule of immunisation, introduced in 1990, has effectively primed immunological memory against both these antigens and that boosting at school entry and at school leaving is effective in increasing levels of immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930669     DOI: 10.1016/s0264-410x(00)00184-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Technical and diagnostic performance of five commercial anti-diphtheria toxoid IgG enzyme-linked immunosorbent assay kits.

Authors:  A Faruq; L Dadson; H Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

2.  Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups.

Authors:  K Caglar; R Karakus; C Aybay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

Review 4.  Adult vaccination against tetanus and diphtheria: the European perspective.

Authors:  B Weinberger
Journal:  Clin Exp Immunol       Date:  2016-07-12       Impact factor: 4.330

5.  Tetanus in patients with chronic wounds - are we aware?

Authors:  Elizabeth Farnworth; Awen Roberts; Aravindan Rangaraj; Uzma Minhas; Samantha Holloway; Keith Harding
Journal:  Int Wound J       Date:  2011-09-19       Impact factor: 3.315

6.  Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia.

Authors:  A Stray-Pedersen; I S Aaberge; A Früh; T G Abrahamsen
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 7.  Do patients with diabetic foot ulcer need booster dose of tetanus vaccine?

Authors:  Zahra Hoseini Tavassol; Zahra Sajjadpour; Shirin Hasani-Ranjbar; Mahnaz Pejman Sani; Hamidreza Aghaei Meybodi; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2022-01-30

8.  Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers.

Authors:  M Borella-Venturini; C Frasson; F Paluan; D DE Nuzzo; G DI Masi; M Giraldo; F Chiara; A Trevisan
Journal:  Epidemiol Infect       Date:  2017-03-15       Impact factor: 4.434

Review 9.  Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2021-05-24

10.  Teenagers' understandings of and attitudes towards vaccines and vaccine-preventable diseases: a qualitative study.

Authors:  S Hilton; C Patterson; E Smith; H Bedford; K Hunt
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.